EP2744573A2 - Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone - Google Patents

Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone

Info

Publication number
EP2744573A2
EP2744573A2 EP12823566.0A EP12823566A EP2744573A2 EP 2744573 A2 EP2744573 A2 EP 2744573A2 EP 12823566 A EP12823566 A EP 12823566A EP 2744573 A2 EP2744573 A2 EP 2744573A2
Authority
EP
European Patent Office
Prior art keywords
lopinavir
ritonavir
copovidone
precipitated
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12823566.0A
Other languages
German (de)
French (fr)
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Dasari Muralidhara Reddy
Bandi Vamsi Krishna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hetero Research Foundation
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Publication of EP2744573A2 publication Critical patent/EP2744573A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • the present invention relates to amorphous mixture of lopinavir and ritonavir co- precipitated on copovidone, process for its preparation and pharmaceutical compositions comprising it.
  • HIV protease inhibitors of human immunodeficiency virus (HIV) protease have been approved for use in the treatment of HIV infection for several years.
  • a particularly effective HIV protease inhibitor was (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(2- l-tetrahydropyrimid-2-onyl)-3-methylbutanoyl)amino-l ,6-diphenylhexane, also known as lopinavir.
  • Lopinavir was known to have ability of inhibiting HIV protease and the HIV infection. Lopinavir was particular effective for the inhibition of HIV protease and for the inhibition of HIV infection when co-administered with Ritonavir.
  • amorphous lopinavir can be prepared by dissolving lopinavir in a solvent such as absolute ethanol, isopropanol, acetone or acetonitrile and then adding the solution to water.
  • Polymorphism is defined as "the ability of a substance to exist as two or more crystalline phases that have different arrangement and/or conformations of the molecules in the crystal Lattice.
  • polymorphs are different crystalline structures of the same pure substance in which the molecules have different arrangements and/or different configurations of the molecules.
  • Different polymorphs may differ in their physical properties such as melting point, solubility, X-ray diffraction patterns, etc. Although those differences disappear once the compound is dissolved, they can appreciably influence pharmaceutically relevant properties of the solid form, such as handling properties, dissolution rate and stability. Such properties can significantly influence the processing, shelf life, and commercial acceptance of a polymorph.
  • Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC) and Infrared spectrometry (IR).
  • XRD X-ray diffraction
  • DSC Differential Scanning Calorimetry
  • IR Infrared spectrometry
  • Solvent medium and mode of crystallization play very important role in obtaining one polymorphic Form over the other.
  • a mixture of lopinavir and ritonavir can exist in different polymorphic Forms, which may differ from each other in terms of stability, physical properties, spectral data and methods of preparation.
  • PCT Publication No. WO 2001/74787 described various polymorphic Forms of lopinavir and processes for their preparation.
  • the Publication described the formation of several polymorphic Forms of lopinavir, which were designated lopinavir crystal Form of Type I hydrated, Type I higher hydrated, Type II isopropanol hemisolvate, Type II isopropanol solvate, Type II ethyl acetate hemisolvate, Type II ethyl acetate solvate, Type II chloroform hemisolvate, Type III ethyl acetate solvated, Type III de-solvated and Type IV non-solvated.
  • PCT publication no. WO 2010/089753 disclosed a de-solvated crystalline Form HI and cyclohexane solvate Form of lopinavir.
  • An unpublished application, IN 303/CHE/201 1 assigned to Hetero research foundation discloses a process for the preparation of lopinavir amorphous Form, lopinavir de-solvated crystalline Form H2 and lopinavir de-solvated crystalline Form H3.
  • Crystalline Form II of ritonavir was disclosed in U.S. patent no. 6,894,171. According to the patent also described crystalline form I of ritonavir.
  • substantially pure amorphous ritonavir can be prepared by adding a solution of ritonavir containing methanol or methylene chloride to an anti-solvent such as hexane or methyl t-butyl ether and isolating.
  • U.S. patent no. 5,559,158 disclosed a solid pharmaceutical composition of ritonavir having the composition is encapsulated in a hard gelatin capsule.
  • U.S. patent no. 5,948,436 disclosed pharmaceutical composition comprising a solution of ritonavir having the solution is encapsulated in a hard gelatin capsule or a soft elastic gelatin capsule.
  • the amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone has been found to be stable over the time and reproducible and so, suitable for pharmaceutical preparations.
  • an object of the present invention is to provide amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone, process for its preparation and pharmaceutical compositions comprising it.
  • the present invention provides amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
  • the present invention provides a process for the preparation of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone, which comprises:
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone and pharmaceutically acceptable excipients.
  • Figure 1 is an X-ray powder diffraction spectrum of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
  • X-ray powder diffraction spectrum was measured on a bruker axs D8 advance X- ray powder diffractometer having a copper- ⁇ radiation.
  • Approximately 1 gm of sample was gently flattered on a sample holder and scanned from 2 to 50 degrees two-theta, at 0.019 degrees two theta per step and a step time of 1 19 seconds. The sample was simply placed on the sample holder. The sample was rotated at 30 rpm at a voltage 40 KV and current 35 mA.
  • room temperature refers to temperature at about 25 to 35°C.
  • amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone there is provided amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
  • the powdered x-ray diffractogram (PXRD) of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone is shown in figure 1.
  • Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone is found to be stable.
  • a process for the preparation of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone which comprises:
  • Lopinavir and ritonavir used in step (a) may be any known crystalline or amorphous Forms.
  • the alcoholic solvent used in step (a) may preferably be a solvent or a mixture of solvents selected from methanol, ethanol, isopropyl alcohol and n-butanol, and more preferably the alcoholic solvent is ethanol.
  • the dissolution in step (a) may be performed, for example, by heating the mixture of lopinavir, ritonavir and copovidone in the solvent.
  • Drying in step (b) may preferably be carried out at about 60 to 70°C under high vacuum.
  • a pharmaceutical composition comprising amorphous mixture of lopinavir and ritonavir co- precipitated on copovidone and pharmaceutically acceptable excipients, and optionally other therapeutic ingredients.
  • the amorphous mixture of lopinavir and ritonavir co- precipitated on copovidone may preferably be formulated into tablets, capsules, suspensions, dispersions, injectables or other pharmaceutical forms.
  • Example 1 was repeated using ritonavir crystalline Form II instead of ritonavir crystalline Form I to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
  • Example 1 was repeated using methanol solvent instead of ethanol solvent to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
  • Example 4 was repeated using methanol solvent instead of ethanol solvent to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
  • Example 1 was repeated using lopinavir de-solvated crystalline Form H2 instead of lopinavir de-solvated crystalline Form HI to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
  • Example 1 was repeated using lopinavir de-solvated crystalline Form H3 instead of lopinavir de-solvated crystalline Form HI to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
  • Example 6 :
  • Example 1 was repeated using lopinavir type I hydrated instead of lopinavir de- solvated crystalline Form HI to obtain amorphous mixture of lopinavir and ritonavir co : precipitated on copovidone. ;
  • Example 1 was repeated using lopinavir type I higher hydrated instead of lopinavir de-solvated crystalline Form HI to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
  • Example 1 Preparation of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone
  • Example 1 was repeated using lopinavir amorphous Form instead of lopinavir de- solvated crystalline Form HI to obtain amorphous mixture of lopinavir and ritonavir co- precipitated on copovidone.
  • Example 9 :
  • Tablet composition comprising Ritonavir and Lopinavir prepared by hot-melt extrusion method:
  • Each 266.6 mg of amorphous mixture of lopinavir and ritonavir contains 200 mg of lopinavir and 50 mg of ritonavir.
  • step no. (ii) surfactant was added to the material of step no. (ii) while mixing for 6-7 minutes, iv) the blend of step no. (iii) was passed through hot melt extruder to form extrudes, v) the extrudes of step no. (iv) were milled using pulverizer and the milled extrudes were sifted through mesh # 30,
  • step no. (v) milled extrudes of step no. (v) were lubricated with colloidal silicon dioxide and sodium stearyl fumarate and finally compressed into tablets and
  • step no. (vi) the tablets of step no. (vi) were film coated using opadry yellow.
  • Tablet composition comprising Ritonavir and Lopinavir prepared by hot-melt extrusion method:
  • Each 133.3mg of 3 ⁇ 1 ⁇ 5 mixture of Ritonavir and Lopinavir contains lOOmg lopinavir and 25mg Ritonavir.
  • step no. (i) the sifted material of step no. (i) were loaded into rapid mixer granulator and mixed for 10 minutes,
  • step no. (ii) surfactant was added to the material of step no. (ii) while mixing for 6-7 minutes, iv) the blend of step no. (iii) was passed through hot melt extruder to form extrudes, v) the extrudes of step no. (iv) were milled using pulverizer and the milled extrudes were sifted through mesh # 30,
  • step no. (v) milled extrudes of step no. (v) were lubricated with colloidal silicon dioxide and sodium stearyl fumarate and finally compressed into tablets and
  • step no. (vi) the tablets of step no. (vi) were film coated using opadry yellow.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone, process for its preparation and pharmaceutical compositions comprising it.

Description

AMORPHOUS MIXTURE OF LOPINAVIR AND RITONAVIR CO-
PRECIPITATED ON COPOVIDONE
This application claims the benefit of Indian Provisional patent Application No. 2828/CHE/2011, filed on Aug 18, 2011, which is incorporated herein by reference.
Filed of the Invention
The present invention relates to amorphous mixture of lopinavir and ritonavir co- precipitated on copovidone, process for its preparation and pharmaceutical compositions comprising it.
Background of the Invention
Inhibitors of human immunodeficiency virus (HIV) protease have been approved for use in the treatment of HIV infection for several years. A particularly effective HIV protease inhibitor was (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(2- l-tetrahydropyrimid-2-onyl)-3-methylbutanoyl)amino-l ,6-diphenylhexane, also known as lopinavir.
Lopinavir was known to have ability of inhibiting HIV protease and the HIV infection. Lopinavir was particular effective for the inhibition of HIV protease and for the inhibition of HIV infection when co-administered with Ritonavir.
The combination of lopinavir and ritonavir is marketed in the dosage strength
133.3:33.3; 80:20; 100:25; and 200:50 under the brand name of KALETRA®.
Ritonavir was chemically, (5S,8S, 10S,1 lS)-10-Hydroxy-2-methyl-5-(l- methylethyl)-l -[2-(l -methylethyl)-4-thiazolyl]-3,6-dioxo-8,1 1 -bis(phenylmethyl)-
2,4,7, 12-tetraazatridecan-13-oic acid 5-thiazolylmethyl ester.
Lopinavir and its process were disclosed in U.S. patent no. 5,914,332. According to the patent, amorphous lopinavir can be prepared by dissolving lopinavir in a solvent such as absolute ethanol, isopropanol, acetone or acetonitrile and then adding the solution to water.
Ritonavir and its process were disclosed in U.S. patent no. 5,541,206.
Polymorphism is defined as "the ability of a substance to exist as two or more crystalline phases that have different arrangement and/or conformations of the molecules in the crystal Lattice. Thus, in the strict sense, polymorphs are different crystalline structures of the same pure substance in which the molecules have different arrangements and/or different configurations of the molecules". Different polymorphs may differ in their physical properties such as melting point, solubility, X-ray diffraction patterns, etc. Although those differences disappear once the compound is dissolved, they can appreciably influence pharmaceutically relevant properties of the solid form, such as handling properties, dissolution rate and stability. Such properties can significantly influence the processing, shelf life, and commercial acceptance of a polymorph. It is therefore important to investigate all solid forms of a drug, including all polymorphic forms, and to determine the stability, dissolution and flow properties of each polymorphic form. Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC) and Infrared spectrometry (IR).
Solvent medium and mode of crystallization play very important role in obtaining one polymorphic Form over the other.
A mixture of lopinavir and ritonavir can exist in different polymorphic Forms, which may differ from each other in terms of stability, physical properties, spectral data and methods of preparation.
PCT Publication No. WO 2001/74787 described various polymorphic Forms of lopinavir and processes for their preparation. The Publication described the formation of several polymorphic Forms of lopinavir, which were designated lopinavir crystal Form of Type I hydrated, Type I higher hydrated, Type II isopropanol hemisolvate, Type II isopropanol solvate, Type II ethyl acetate hemisolvate, Type II ethyl acetate solvate, Type II chloroform hemisolvate, Type III ethyl acetate solvated, Type III de-solvated and Type IV non-solvated.
A process for the preparation of lopinavir amorphous Form was disclosed in PCT publication nos. WO 2009/004653 and WO 2009/019661.
PCT publication no. WO 2010/089753 disclosed a de-solvated crystalline Form HI and cyclohexane solvate Form of lopinavir. An unpublished application, IN 303/CHE/201 1 assigned to Hetero research foundation discloses a process for the preparation of lopinavir amorphous Form, lopinavir de-solvated crystalline Form H2 and lopinavir de-solvated crystalline Form H3.
An unpublished application, IN 665/CHE/2011 assigned to Hetero research foundation discloses a novel amorphous Form of lopinavir and ritonavir mixture.
Crystalline Form II of ritonavir was disclosed in U.S. patent no. 6,894,171. According to the patent also described crystalline form I of ritonavir.
U.S. patent no. 7,205,413 disclosed crystalline Form III, Form IV and Form V of ritonavir.
U.S. patent no. 7,148,359 disclosed a substantially pure amorphous ritonavir.
Process for the preparation of substantially pure amorphous ritonavir was disclosed in U.S. patent no. 7,183,416. According to the patent, substantially pure amorphous ritonavir can be prepared by adding a solution of ritonavir containing methanol or methylene chloride to an anti-solvent such as hexane or methyl t-butyl ether and isolating.
Process for the preparation of amorphous ritonavir was described in Journal of Pharmaceutical Sciences, Vol. 90, No. 8, P. 1015-1025 by heating the ritonavir to 135°C in oil bath, followed by rapid cooling using liquid nitrogen or cold water.
Process for the preparation of amorphous ritonavir was described in Journal of Pharmaceutical Sciences, Vol. 91, No. 8, P. 1863-1872 by freeze-drying.
U.S. patent no. 5,559,158 disclosed a solid pharmaceutical composition of ritonavir having the composition is encapsulated in a hard gelatin capsule.
U.S. patent no. 5,948,436 disclosed pharmaceutical composition comprising a solution of ritonavir having the solution is encapsulated in a hard gelatin capsule or a soft elastic gelatin capsule.
U.S. patent no. 7,364,752 disclosed compositions of ritonavir prepared by solid dispersion technique.
Preparation of amorphous Form of ritonavir was described in Journal of the American association of pharmaceutical scientists, Vol. 13, No. 9, P. 7473-7476, September 1996 by spray drying of the ritonavir on polyvinylpyrillodone (PVP) and ethanol. Similarly, preparation of amorphous Form of ritonavir was described by layering of the ritonavir on microcrystalline cellulose and silicon dioxide.
It was observed that the amorphous material obtained by the process described in U.S. patent no. 7,181,416 was changed into molten state within about 30 minutes. Thus, the amorphous form obtained by the process of U.S. patent no. 7, 181,416 was shown to be unstable.
The amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone has been found to be stable over the time and reproducible and so, suitable for pharmaceutical preparations.
Thus, an object of the present invention is to provide amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone, process for its preparation and pharmaceutical compositions comprising it.
Summary of the Invention
In one aspect, the present invention provides amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
In another aspect, the present invention provides a process for the preparation of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone, which comprises:
i) dissolving a mixture of lopinavir, ritonavir, copovidone, aerosil and span-20 in an alcoholic solvent; and
ii) removing the solvent by drying at about 50 to 80°C to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
Yet in another aspect, the present invention provides a pharmaceutical composition comprising amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone and pharmaceutically acceptable excipients.
Brief Description of the Drawings
Figure 1 is an X-ray powder diffraction spectrum of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone. X-ray powder diffraction spectrum was measured on a bruker axs D8 advance X- ray powder diffractometer having a copper-Κα radiation. Approximately 1 gm of sample was gently flattered on a sample holder and scanned from 2 to 50 degrees two-theta, at 0.019 degrees two theta per step and a step time of 1 19 seconds. The sample was simply placed on the sample holder. The sample was rotated at 30 rpm at a voltage 40 KV and current 35 mA.
Detailed Description of the Invention
The term "room temperature" refers to temperature at about 25 to 35°C.
According to one aspect of the present invention, there is provided amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone. The powdered x-ray diffractogram (PXRD) of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone is shown in figure 1.
Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone is found to be stable.
According to another aspect of the present invention, there is provided a process for the preparation of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone, which comprises:
i) dissolving a mixture of lopinavir, ritonavir, copovidone, aerosol and span-20 in an alcoholic solvent; and
ii) removing the solvent by drying at about 50 to 80°C to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
Lopinavir and ritonavir used in step (a) may be any known crystalline or amorphous Forms.
The alcoholic solvent used in step (a) may preferably be a solvent or a mixture of solvents selected from methanol, ethanol, isopropyl alcohol and n-butanol, and more preferably the alcoholic solvent is ethanol.
The dissolution in step (a) may be performed, for example, by heating the mixture of lopinavir, ritonavir and copovidone in the solvent.
Drying in step (b) may preferably be carried out at about 60 to 70°C under high vacuum. According to another aspect of the present invention, there is provided a pharmaceutical composition comprising amorphous mixture of lopinavir and ritonavir co- precipitated on copovidone and pharmaceutically acceptable excipients, and optionally other therapeutic ingredients. The amorphous mixture of lopinavir and ritonavir co- precipitated on copovidone may preferably be formulated into tablets, capsules, suspensions, dispersions, injectables or other pharmaceutical forms.
The invention will now be further described by the following examples, which are illustrative rather than limiting.
Examples
Example 1 :
Preparation of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone
A mixture of lopinavir de-solvated crystalline Form HI (75 gm), ritonavir crystalline Form I (18.75 gm), copovidone (5.68 gm), aerosil (0.0066 gm) and span-20 (0.55 gm) was dissolved in ethanol (400 ml) under stirring at room temperature. The solution was then heated to 40 to 45°C to obtain a clear solution. The resulting solution was subjected to dry under high vacuum at 60 to 65°C for 10 hours to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone. Example 2:
Preparation of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone
Example 1 was repeated using ritonavir crystalline Form II instead of ritonavir crystalline Form I to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
Example 3:
Preparation of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone
Example 1 was repeated using methanol solvent instead of ethanol solvent to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone. Example 4:
Preparation of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone
Example 1 was repeated using lopinavir de-solvated crystalline Form H2 instead of lopinavir de-solvated crystalline Form HI to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
Example 5:
Preparation of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone
Example 1 was repeated using lopinavir de-solvated crystalline Form H3 instead of lopinavir de-solvated crystalline Form HI to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone. Example 6:
Preparation of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone
Example 1 was repeated using lopinavir type I hydrated instead of lopinavir de- solvated crystalline Form HI to obtain amorphous mixture of lopinavir and ritonavir co: precipitated on copovidone. ;
Example 7:
Preparation of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone
Example 1 was repeated using lopinavir type I higher hydrated instead of lopinavir de-solvated crystalline Form HI to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
Example 8:
Preparation of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone Example 1 was repeated using lopinavir amorphous Form instead of lopinavir de- solvated crystalline Form HI to obtain amorphous mixture of lopinavir and ritonavir co- precipitated on copovidone. Example 9:
Tablet composition comprising Ritonavir and Lopinavir prepared by hot-melt extrusion method:
# Amorphous mixture of lopinavir and ritonavir was prepared as per any of the examples 1 -8.
Each 266.6 mg of amorphous mixture of lopinavir and ritonavir contains 200 mg of lopinavir and 50 mg of ritonavir.
Manufacturing process:
i) Amorphous mixture of Ritonavir and Lopinavir, copovidone and colloidal silicon dioxide were sifted through mesh # 30, ii) the sifted material of step no. (i) were loaded into rapid mixer granulator and mixed for 10 minutes,
iii) surfactant was added to the material of step no. (ii) while mixing for 6-7 minutes, iv) the blend of step no. (iii) was passed through hot melt extruder to form extrudes, v) the extrudes of step no. (iv) were milled using pulverizer and the milled extrudes were sifted through mesh # 30,
vi) milled extrudes of step no. (v) were lubricated with colloidal silicon dioxide and sodium stearyl fumarate and finally compressed into tablets and
vii) the tablets of step no. (vi) were film coated using opadry yellow.
Example 10:
Tablet composition comprising Ritonavir and Lopinavir prepared by hot-melt extrusion method:
Αηιθ ΙιουΒ mixture of Ritonavir and Lopinavir was prepared as per any of the examples 1-7.
Each 133.3mg of 3Γηοφ1ιου5 mixture of Ritonavir and Lopinavir contains lOOmg lopinavir and 25mg Ritonavir.
Manufacturing process:
i) Amorphous mixture of Ritonavir and Lopinavir, copovidone and colloidal silicon dioxide were sifted through mesh # 30,
ii) the sifted material of step no. (i) were loaded into rapid mixer granulator and mixed for 10 minutes,
iii) surfactant was added to the material of step no. (ii) while mixing for 6-7 minutes, iv) the blend of step no. (iii) was passed through hot melt extruder to form extrudes, v) the extrudes of step no. (iv) were milled using pulverizer and the milled extrudes were sifted through mesh # 30,
vi) milled extrudes of step no. (v) were lubricated with colloidal silicon dioxide and sodium stearyl fumarate and finally compressed into tablets and
vii) the tablets of step no. (vi) were film coated using opadry yellow.

Claims

We claim:
1. Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
2. The amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone of claim 1, having a powder X-ray diffractogram as shown in figure 1.
3. A process for the preparation of amorphous mixture of lopinavir and ritonavir co- precipitated on copovidone, which comprises:
i) dissolving a mixture of lopinavir, ritonavir, copovidone, aerosol and span-20 in an alcoholic solvent; and
ii) removing the solvent by drying at about 50 to 80°C to obtain amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone.
4. The process as claimed in claim 3, wherein the alcoholic solvent used in step (a) is a solvent or a mixture of solvents selected from methanol, ethanol, isopropyl alcohol and n-butanol.
5. The process as claimed in claim 4, wherein the alcoholic solvent is ethanol.
6. The process as claimed in claim 3, wherein the drying in step (b) is carried out at about 60 to 70°C under high vacuum.
7. A pharmaceutical composition comprising amorphous Form of a mixture of lopinavir and ritonavir co-precipitated on copovidone and pharmaceutically acceptable excipients, and optionally other therapeutic ingredients.
8. A pharmaceutical composition comprising i) amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone, ii) a water-soluble polymer and iii) a surfactant wherein the composition is prepared by hot melt extrusion method.
9. The pharmaceutical composition according to claim 8, selected from a tablet, a capsule and a granule.
10. A process for preparing compositions of amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone by hot melt extrusion method involves:
i) sifting and blending of amorphous mixture of lopinavir and ritonavir co- precipitated on copovidone, water soluble polymer and one or more pharmaceutically acceptable excipients to form a dry mix,
ii) blending the dry mix of step no. (i) with surfactant, iii) passing the material of step no. (ii) through hot melt extruder to form extrudes followed by milling and sifting and,
iv) blending the milled extrudes of step no. (iii) with remaining portion of excipients and finally compressing into tablets.
11. The pharmaceutical composition according to claim 8 and 10, wherein said water- soluble polymer is selected from copovidone and polyethylene oxide and said surfactant is selected from sorbitan monolaurate and polyoxyl 35 castor oil.
EP12823566.0A 2011-08-18 2012-08-13 Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone Withdrawn EP2744573A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2828CH2011 2011-08-18
PCT/IN2012/000549 WO2013024494A2 (en) 2011-08-18 2012-08-13 Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone

Publications (1)

Publication Number Publication Date
EP2744573A2 true EP2744573A2 (en) 2014-06-25

Family

ID=47715537

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12823566.0A Withdrawn EP2744573A2 (en) 2011-08-18 2012-08-13 Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone

Country Status (2)

Country Link
EP (1) EP2744573A2 (en)
WO (1) WO2013024494A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
ES2844848T3 (en) * 2015-04-21 2021-07-22 Eiger Biopharmaceuticals Inc Pharmaceutical compositions comprising Lonafarnib and Ritonavir
WO2019094688A1 (en) * 2017-11-10 2019-05-16 Dispersol Technologies, Llc Improved drug formulations
CN114557967B (en) * 2022-03-17 2023-06-02 乐普制药科技有限公司 Preparation method of ritonavir solid dispersion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2063862A2 (en) * 2006-09-04 2009-06-03 Matrix Laboratories Ltd Pharmaceutical formulation for use in hiv therapy
EP2279728A1 (en) * 2009-07-31 2011-02-02 Ranbaxy Laboratories Limited Solid dosage forms of HIV protease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013024494A3 *

Also Published As

Publication number Publication date
WO2013024494A3 (en) 2013-04-25
WO2013024494A2 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
US11911511B2 (en) Anticancer compositions
JP7258924B2 (en) Dosage form compositions containing inhibitors of Bruton's tyrosine kinase
EP1793824B1 (en) New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders
JP6770035B2 (en) Amorphous letermovir and its solid pharmaceutical formulation for oral administration
US8227463B2 (en) Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same
CA2847860A1 (en) Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
WO2013024494A2 (en) Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone
TWI831848B (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
CN102905707A (en) Pharmaceutical preparation comprising phenylalanine derivative
WO2016092561A2 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
WO2016135755A1 (en) Amorphous apremilast, premixes thereof, and novel crystalline forms of apremilast
TW202227067A (en) Amorphous form of a malt1 inhibitor and formulations thereof
CN104622836B (en) Sofosbuvir coated tablet and preparation method thereof
US9096556B2 (en) Amorphous ritonavir co-precipitated
JP2019055960A (en) Solid forms of pharmaceutically active compound
CA2937942A1 (en) Fixed-dose combinations of antiviral compounds
US20150080420A1 (en) Amorphous form of lopinavir and ritonavir mixture
TWI726978B (en) A pharmaceutical composition comprising quinoline derivatives or salt thereof
EP3510996A1 (en) Pharmaceutical compositions of betrixaban
EP3102210A1 (en) Pharmaceutical composition of selective hcv ns3/4a inhibitors
HUE027829T2 (en) Dosage form comprising non-crystalline lopinavir and crystalline ritonavir
CZ20199A3 (en) Pharmaceutical composition of crystalline enzalutamide and preparing it

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140314

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150303